Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
CR

CRL

Market Closed

Charles River Laboratories International, Inc.

NYSEHealthcareMedical - Diagnostics & Research
US
19.00K employees
CEO: Birgit Girshick
Founded: 2000
$337.97
+$0.00(+NaN%)
Market Cap
16.19B
Beta
1.34
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Charles River Laboratories appears significantly overvalued, with a current price 52% above its $158 fair value, driven by weak profitability and low growth scores. Valuation methods, especially DCF and Monte Carlo, indicate downside risk exceeding 100%, reflecting volatility and financial health concerns. High confidence in valuation suggests elevated investment risk despite some trading range support.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore CRL

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

CRL in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Medical - Diagnostics & Research

Browse industry stocks →